Article

The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication

2025-03-11

Abstract excerpt

<h4>ABSTRACT</h4> Nirmatrelvir, the active compound of the drug Paxlovid, inhibits the Main protease of SARS-CoV-2 (M Pro , 3CL Pro , NSP5). Its therapeutic application reduces but does not abolish the progression of COVID-19 in humans. Here we report a strong synergy of Nirmatrelvir with inhibitors of the ER chaperone GRP78 (HSPA5, BiP). Combining Nirmatrelvir with the GRP78-antagonizing drug candidate HA15 st...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 845e3232-4270-5e4a-b348-e6f5def595dd
DOI: 10.1101/2025.03.09.642200

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replicationDOI 10.1101/2025.03.09.642200Read

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)Semantic proximity Read

Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected miceSemantic proximity Read

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernSemantic proximity Read

Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus MacaquesSemantic proximity Read

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity Read

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvirSemantic proximity Read

Remdesivir-Nirmatrelvir Combination: In Vitro Activity and a Case ReportSemantic proximity Read

Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivirSemantic proximity Read

Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of NirmatrelvirSemantic proximity Read

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvirSemantic proximity Read

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In VitroSemantic proximity Read